[G25-27] Concizumab (haemophilia A, haemophilia B) – Addendum to Projects A25-55 and A25-56
Last updated 16.10.2025
Project no.:
G25-27
Commission:
Commission awarded on 09.09.2025 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Health Economics
Topic:
Haematology
Note:
If, in the course of the discussions on a commission of the G-BA, a need for further revision arises, IQWiG presents its report in the form of an addendum. The G-BA decides on the number of patients in the SHI target population.
DOI:
https://doi.org/10.60584/G25-27
| Project no. | Title | Status |
|---|---|---|
| A25-55 | Concizumab (haemophilia A) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A25-56 | Concizumab (haemophilia B) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
16-10-2025 A G-BA decision was published.
G-BA documents on this decision